Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Arterial prosthesis – Having plural layers
Reexamination Certificate
2001-11-09
2004-06-08
McDermott, Corrine (Department: 3738)
Prosthesis (i.e., artificial body members), parts thereof, or ai
Arterial prosthesis
Having plural layers
C623S001420
Reexamination Certificate
active
06746482
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates generally to medical devices and products. More specifically the present invention relates to medical devices and products that are coated with a material to provide improved characteristics.
There are literally thousands of products that are used in the medical industry for a variety of treatments and therapies. The surface characteristics of some of these products may be critical to the ability of the products to function. Such products run the gamut from membranes used in blood and cell separation devices, theracyte devices, dialyzers, arterial filters, catheters, wound drains, vascular grafts, and heart valve tissues.
For example, a slippery or low friction surface property is required in various medical devices. These devices include wound drains, chest tubes, guide wires, catheters, and angioplasty products. A lubricious surface is desirable on these devices as it reduces pain to the patient during insertion and/or removal of the device.
Moreover, with respect to wound drains, these devices are employed in various surgical sites to remove biological fluids that can accumulate in the wound sites following surgery. Major issues with such devices can include occlusion of the lumen with clots on tissue debris. This can lead to swelling and infection. Additionally, these devices can adhere to adjacent tissue.
It is also desirable, on a number of medical products, to provide a surface that has anti-microbial properties. Likewise, medical devices that have surfaces that are non-thrombogenic are valuable in many applications.
In certain applications, it is also desirable to provide a surface that binds to certain type of cells or agents. For example, such products may be desirable for implantable biological tissue such as bioprosthetic valves.
By way of further and more detailed example, in processing whole blood for therapeutic administration to patients, it is desirable to separate the various cellular components. In particular, it is desirable to remove leukocytes because of their role in mediating immunologic reactions which can cause adverse clinical events such as allosensitization. For a review of adverse clinical sequellae to transfusion, see Sekiguchi, et al., Leucocyte-depleted blood products and their clinical usefulness, Ch. 5, pg. 26-33, from
The Role of Leucocyte Depletion in Blood Transfusion Practice
(1988). Furthermore, leukocytes are unessential for therapeutic supplementation of cell deficiencies in patients involving platelets and red cells. Thus, filter systems have been devised for passaging blood cells in order to remove leukocytes while allowing platelets or red blood to pass through for subsequent recovery.
There have been a number of approaches reported for leukocyte depletion. U.S. Pat. No. 4,330,410 discloses a packed fiber mass with leukodepletion properties comprising fibers of cellulose acetate, acrylonitrile, polyamide, or polyester. U.S. Pat. No. 4,925,572 discloses the use of a gelatin coating to inhibit red blood cell (RBC) and platelet adhesion. Leukodepletion is accomplished primarily through physical entrainment of the cells in the fiber body, and adhesion of RBCs and platelets results from the gelatin coating. U.S. Pat. No. 4,936,998 discloses a strategy for leukodepletion in which a hydrophilic monomer containing hydroxyl or amido groups and functional nitrogen-containing groups such as primary or secondary amino groups is coated onto a filter matrix of known fibers such as polyester, polyamide, etc.
Modification of fiber surfaces has also been used to obtain materials with improved cell separation properties. For example, U.S. Pat. No. 4,130,642 discloses a packed column in which the packing material comprises an Egyptian cotton which has been de-fatted and bleached so that RBC readily pass through the column.
Some separation strategies involve multiple steps. U.S. Pat. No. 4,925,572 discloses a multistep method comprising an upstream porous element for removal of gels, a second element of finer porosity for removal of aggregated matter, and a final filtration step involving common fibers to which surface tension-reducing and improved wetting are obtained by radiation grafting of biocompatible moieties. Further description of leukodepletion methods is contained in Rikumaru, et al., Advanced methods for leucocyte removal by blood filtration, Ch. 6, pgs. 35-40, from
The Role of Leucocyte Depletion in Blood Transfusion Practice
(1988).
It is of utmost importance in designing leukodepletion strategies in which one goal is to obtain good recoveries of platelets and RBCs, to achieve separations without activating platelets or complement. It is also important that any coatings utilized to enhance the separations not be leached into solution, since the recovered cells are intended for intravascular administration to patients. One approach embodies a filter composed of a porous polymer material with continuous pore structure having a coating combining a nitrogen-containing functional group with a polyethylene oxide chain having 2-15 repeating units (See Jap. Kokai Patent Application No. Hei 5 [1993]-194243). This material is said to entrap leukocytes while giving high yields of platelets.
The use of polyalkylene oxide polymers is well-known in the construction of biocompatible materials, because of its low biological activity in activating cellular and humoral components of blood, and in stimulating immune responses. However, the inertness of the polyalkylene oxide polymers may also interfere with the degree of separation that can be obtained with cell separation filters, unless combined with functional groups that enhance separation parameters. A suitable combination of coating components has not heretofore been developed which is efficacious for cell separations from whole blood as distinct from semi-purified cell suspension mixtures.
Likewise, for a number of other medical products, a suitable material or combination for coating products has not been provided.
SUMMARY OF THE INVENTION
The present invention provides improved methods for coating medical products and devices. Additionally, the present invention provides improved coated medical devices and products. More specifically, the present invention provides improved medical devices and methods of manufacturing same.
Summarizing briefly, the present invention provides, in an embodiment, medical devices which are coated, at least in part, with polyaklylene oxide and a functional group that modifies the surface properties of the device, e.g., heparin, magainin, or chlorhexidine, in a one step process. The polyaklylene oxide allows the heparin to attach to the tubing. In this regard, the polymer attaches to the surface and the heparin.
Both high and low molecular weight polyalkylene oxide compounds can be used. Low molecular weight polyaklylene oxide has a generally linear structure Y-PEO-Y and high molecular weight polyalkylene oxide compound has the general structure Y-PEO-R-PEO-Y, wherein Y is a reactive moiety selected from an oxycarbonylimidazole, tresyl-, tosyl-, N-hydroxysuccinimidyl, and p-nitrophenyl-activated esters; acrylates; glycidyl ethers; aldehydes; and amines. The oxycarbonylimidazole leaving group is preferred, as will be apparent from the detailed specification, R is a spacer molecule (a chemical backbone) consisting of either bisphenol A (4,4′-(1-methylethylidene)bisphenol) or bisphenol B (4,4′-(1-methylpropylidene)bisphenol), and PEO stands for polyalkylene oxide.
In an embodiment, the present invention provides a medical device comprising a body member and a coating on at least a portion of the body member comprising a product of a polyalkylene oxide and a functional group that modifies the surface. In an embodiment, the functional group is heparin.
In an embodiment, the functional group is chosen from the group consisting of anti-coagulants, heparin, hirudin, anti-microbial, proteins, peptides, and biopolymers.
In an embodiment, the portion of the body member is constructed at least in pa
Barrett Joseph
Baxter International Inc.
Bell Boyd & Lloyd LLC
McDermott Corrine
Phan Hieu
LandOfFree
Method for producing medical devices and devices so produced does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing medical devices and devices so produced, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing medical devices and devices so produced will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3347616